ClinicalTrials.gg
CompletedNCT01636206SONATAUpdated Jun 11, 2021Results posted

Safety Study of Lifitegrast to Treat Dry Eye

A Phase 3 interventional study of Lifitegrast and Placebo in Dry Eye Disease, sponsored by Shire. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing lifitegrast in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. lifitegrast · Dry Eye Syndromes.

Enrollment
6th of 22
332 · median 38
Started
2012
with 1 other
Phase 3
5 of 22
none open now
Registered
3rd of 22
by date
Lead sponsor
5 of 22
Shire

Among the 22 studies testing lifitegrast in Dry Eye Syndromes, this one is the 6th largest by enrollment, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 3rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 22 studies testing lifitegrast in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lifitegrast

lifitegrast: first FDA approval 2016 (XIIDRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing lifitegrast in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to read, sign and date the and HIPAA documents
  • Willing and able to comply with all study procedures
  • Be at least 18 years of age
  • Patient-reported history of dry eye in both eyes
  • A negative urine pregnancy test if female of and must use adequate throughout the study period

Exclusion criteria

Exclusion Criteria:

  • Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy
  • Unwilling to avoid wearing contact lenses for 24h prior to Visit 1 and for some duration during the study
  • Any blood donation or significant loss of blood within 56 days of Visit 1
  • Any history of immunodeficiency disorder, positive , , C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.
  • Use of any prohibited medications during the appropriate pre-study and at any time during the study unless otherwise specified
  • Any significant illness that could interfere with study parameters
  • History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.
  • Known history of alcohol and/or drug abuse
  • Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet cells (as with Vitamin A deficiency)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Experimental
    Lifitegrast

    Active

    Drug: Lifitegrast

Interventions

  • Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: \~1 year

  • DrugPlacebo

    Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: \~1 year

06

What researchers measure

Primary outcomes

  1. Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year

    Time frame: Day 0 to Day 360

07

Results

Posted Oct 3, 2016

Participant flow

Participant flow — Overall Study
MilestonePlaceboLifitegrast
Started111221
Completed92170
Not completed1951

Outcome measures

PrimaryNumber of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year
Time frame:
Day 0 to Day 360
Reported as:
Number · participants
Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year
participantsPlaceboLifitegrast
Ocular TEAE38118
Non-ocular TEAE40104

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—6/111 (5.4%)22/111 (19.8%)
Lifitegrast—9/220 (4.1%)92/220 (41.8%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlaceboLifitegrast
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/1110/220
ArrhythmiaCardiac disorders1/1110/220
Chest painGeneral disorders1/1110/220
Spinal fractureInjury, poisoning and procedural complications1/1110/220
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1110/220
Atrioventricular blockCardiac disorders0/1111/220
Myocardial infarctionCardiac disorders0/1111/220
PneumoniaInfections and infestations0/1111/220
Urinary tract infectionInfections and infestations0/1111/220
Hip fractureInjury, poisoning and procedural complications0/1111/220
Most frequent other events
Most frequent other events
EventPlaceboLifitegrast
DysgeusiaNervous system disorders2/11136/220
Instillation site irritationGeneral disorders5/11133/220
Instillation site reactionGeneral disorders2/11129/220
Visual acuity reducedEye disorders7/11125/220
Dry eyeEye disorders6/1114/220

Baseline characteristics

Randomized population.

Age, Continuous
Age, Continuous(years)PlaceboLifitegrastTotal
Mean61.0 ± 13.1858.8 ± 12.3959.5 ± 12.68
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLifitegrastTotal
Female85165250
Male265682
08

Study locations

23 sites
  • SONATA Investigational Site
    Artesia, California 90701, United States
  • SONATA Investigational Site
    Hemet, California 92545, United States
  • SONATA Investigational Site
    Laguna Hills, California 92653, United States
  • SONATA Investigational Site
    Lancaster, California 93534, United States
  • SONATA Investigational Site
    Montebello, California 90640, United States
  • SONATA Investigational Site
    Parker, Colorado 80134, United States
  • SONATA Investigational Site
    Boynton Beach, Florida 33426, United States
  • SONATA Investigational Site
    Roswell, Georgia 30076, United States
  • SONATA Investigational Site
    Hoffman Estates, Illinois 60169, United States
  • SONATA Investigational Site
    Edgewood, Kentucky 41017, United States
  • SONATA Investigational Site
    Lexington, Kentucky 40509, United States
  • SONATA Investigational Site
    Stillwater, Minnesota 55082, United States
  • SONATA Investigational Site
    Pennington, New Jersey 08534, United States
  • SONATA Investigational Site
    Woodland Park, New Jersey 07424, United States
  • SONATA Investigational Site
    Rochester, New York 14618, United States
  • SONATA Investigational Site
    Rockville Centre, New York 11570, United States
  • SONATA Investigational Site
    Charlotte, North Carolina 28210, United States
  • SONATA Investigational Site
    High Point, North Carolina 27262, United States
  • SONATA Investigational Site
    Cleveland, Ohio 44115, United States
  • SONATA Investigational Site
    Doylestown, Pennsylvania 18902, United States
  • SONATA Investigational Site
    Mount Pleasant, South Carolina 29464, United States
  • SONATA Investigational Site
    Chattanooga, Tennessee 37411, United States
  • SONATA Investigational Site
    Houston, Texas 77204, United States
09

References and documents

Publications

  • Donnenfeld ED, Karpecki PM, Majmudar PA, Nichols KK, Raychaudhuri A, Roy M, Semba CP. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Cornea. 2016 Jun;35(6):741-8. doi: 10.1097/ICO.0000000000000803. PubMed 27055211 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Mar 2014, 16 months.

Results were first posted in Oct 2016, 2 years 7 months after primary completion. A results delay was requested in Apr 2014.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 16 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2012
First posted
Jul 10, 2012
StartActual
Oct 16, 2012
Primary completionActual
Mar 3, 2014
CompletionActual
Mar 3, 2014
Results delay requested
Apr 7, 2014
Results first posted
Oct 3, 2016
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01636206
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Oct 16, 2012
Primary completion
Mar 3, 2014
Completion
Mar 3, 2014
Results posted
Oct 3, 2016
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifitegrast

Start the discussion